Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

  title={Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.},
  author={Laura J. Johnston and Janice Brown and Judith A Shizuru and K Stockerl-Goldstein and Monic Jain Stuart and Karl G. Blume and Robert S. Negrin and Nelson J Chao},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  volume={11 1},
We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety of this regimen. Rapamycin was begun as second-line (n = 9) or more than second-line (n = 10) therapy. With a median follow-up of 42 months, 16 patients were evaluable for response. Nine patients discontinued rapamycin because of poor compliance/patient request (n = 2… CONTINUE READING